Metastatic Neoplasm Clinical Trial
Official title:
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies
Verified date | April 2024 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objectives: - Part 1 - To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors. - To define the MTD and RP2D for the combination of SAR442720 and pembrolizumab in participants with solid tumors. - Part 2 - To determine the anti-tumor activity of SAR442720 in combination with pembrolizumab. - Part 3A - To define the MTD and RP2D for the combination of SAR442720 and adagrasib in participants with KRAS G12C NSCLC - To characterize the safety and tolerability of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC - Part 3B - To determine the anti-tumor activity of SAR442720 in combination with adagrasib in participants with KRAS G12C NSCLC - Part 4 - To evaluate the impact of food on the PK of SAR442720 when dosed with pembrolizumab. - To evaluate the impact of the formulations (formulation 1 and formulation 2) on the PK of SAR442720 when dosed with pembrolizumab. Secondary Objectives: - Part 1 - To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720. - To estimate the anti-tumor effects of SAR442720 with pembrolizumab. - Part 2 - To assess the safety profile of SAR442720 combined with pembrolizumab. - To assess other indicators of anti-tumor activity. - To assess the PK of SAR442720 with pembrolizumab, and the PK of pembrolizumab with SAR442720. - Part 3A - To characterize the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720. - To estimate the anti-tumor effects of SAR442720 with adagrasib - Part 3B - To assess the safety profile of SAR442720 with adagrasib in participants with KRAS G12C NSCLC. - To assess other indicators of anti-tumor activity. - To assess the PK of SAR442720 with adagrasib, and the PK of adagrasib with SAR442720. - Part 4 - To assess the safety and tolerability of SAR442720 formulations with pembrolizumab - To estimate the anti-tumor effects of SAR442720 with pembrolizumab.
Status | Terminated |
Enrollment | 65 |
Est. completion date | April 4, 2024 |
Est. primary completion date | April 4, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants must be = 18 years of age. - Histologically proven diagnosis of advanced solid tumors. - Participants must have one or more of the following molecular aberrations (Part 1): KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations. - Participants must have following molecular aberration (Part 3A and 3B): - KRAS G12C mutation. - At least 1 measurable disease per RECIST 1.1 criteria. - Eastern Cooperative Oncology Group (ECOG) performance status 0-1. - Woman of childbearing potential must agree to follow contraceptive guidance. - Capable of giving signed informed consent. Exclusion Criteria: - Predicted life expectancy <3 months. - Primary central nervous system (CNS) tumors. - Symptomatic or impending cord compression. Stable CNS disease is allowed. - History of cerebrovascular stroke or transient ischemic attack within previous 6 months. - Prior solid organ or hematologic transplant. - History or current retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vascular occlusion (RVO), neovascular macular degeneration. - Any clinically significant cardiac disease. - Active, known or suspected autoimmune disease. - History of or current interstitial lung disease or pneumonitis. - Receipt of a live-virus vaccination within 28 days, viral vaccine that do not contain live virus within 7 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted. - Known infection with human immunodeficiency virus (HIV), known uncontrolled hepatitis B infection, active tuberculosis, or severe infection requiring parenteral antibiotic treatment. - Inadequate hematologic, hepatic and renal function. - Known second malignancy. - Impairment of gastrointestinal function. - Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol. - History of severe allergic reaction to any of the study intervention components. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
Argentina | Investigational Site Number : 0320002 | Buenos Aires | |
Argentina | Investigational Site Number : 0320001 | Caba | Buenos Aires |
Argentina | Investigational Site Number : 0320004 | Caba | Ciudad De Buenos Aires |
Argentina | Investigational Site Number : 0320003 | Rosario | Santa Fe |
Australia | Investigational Site Number : 0360003 | Heidelberg West | Victoria |
Australia | Investigational Site Number : 0360002 | Randwick | New South Wales |
Australia | Investigational Site Number : 0360001 | Woolloongabba | Queensland |
Chile | Investigational Site Number : 1520001 | Santiago | Reg Metropolitana De Santiago |
Chile | Investigational Site Number : 1520002 | Temuco | |
Chile | Investigational Site Number : 1520003 | Viña del Mar | Valparaíso |
Korea, Republic of | Investigational Site Number : 4100003 | Cheongju-si | Chungcheongbuk-do |
Korea, Republic of | Investigational Site Number : 4100002 | Seongnam-si, Gyeonggi-do | |
Korea, Republic of | Investigational Site Number : 4100001 | Seoul | Seoul-teukbyeolsi |
Netherlands | Investigational Site Number : 5280001 | Leiden | |
Spain | Investigational Site Number : 7240001 | Madrid / Madrid | Madrid, Comunidad De |
Spain | Investigational Site Number : 7240002 | Madrid / Madrid | Madrid, Comunidad De |
Spain | Investigational Site Number : 7240003 | Valencia / Valencia | Valenciana, Comunidad |
Taiwan | Investigational Site Number : 1580002 | Tainan | |
Taiwan | Investigational Site Number : 1580001 | Taipei | |
United States | ~University of Texas - MD Anderson Cancer Center Site Number : 8400001 | Houston | Texas |
United States | University of California Irvine Medical Center Site Number : 8400002 | Orange | California |
Lead Sponsor | Collaborator |
---|---|
Sanofi | Mirati Therapeutics Inc., Revolution Medicines, Inc. |
United States, Argentina, Australia, Chile, Korea, Republic of, Netherlands, Spain, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events (AEs) SAR442720 and pembrolizumab | Part 1:
Incidence, nature, and severity of treatment emergent AEs and serious adverse events (SAEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 for the combination of SAR442720 and pembrolizumab. |
21 days | |
Primary | Incidence of study-drug related Dose Limiting Toxicities (DLTs) | Part 1 and 3A:
Incidence of study drug-related dose-limiting toxicities (DLTs) in Cycle 1. |
up to 2 years | |
Primary | Objective Response Rate (ORR) | Part 2 and 3B:
Objective response rate defined as the proportion of participants who have a confirmed CR or partial response (PR) determined by investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 |
up to 2 years | |
Primary | Incidence of Adverse Events (AEs) SAR442720 and adagrasib | Part 3A:
Incidence, nature, and severity of TEAEs and SAEs, graded according to NCI CTCAEv5.0 for the combination of SAR442720 and adagrasib. |
up to 2 years | |
Primary | Part 4: Plasma concentrations of SAR442720 in combination with pembrolizumab under impact of food | up to 2 years | ||
Secondary | Part 1 and 2: Plasma concentrations of SAR442720 | up to 2 years | ||
Secondary | Part 1 and 2: Serum concentration of pembrolizumab | up to 2 years | ||
Secondary | Objective response rate (ORR) Part 1 and Part 4 | Part 1 and Part 4:
Objective response rate of SAR442720 and pembrolizumab in all participants. ORR of combination therapy with SAR442720 and pembrolizumab will be based on Response Evaluation Criteria in Solid Tumors (RECIST) v1. |
up to 2 years | |
Secondary | Duration of response (DoR) | Part 1 and Part 2 and 3B:
Duration of response per RECIST v1.1 is defined as the interval from the first documentation of CR (complete response) or PR (partial response) to the earlier of the first documentation of definitive disease progression or death due to any cause, whichever occurs first. |
up to 2 years | |
Secondary | Incidence of Adverse Events | Part 2 and 3B and Part 4:
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the NCI CTCAE v5 for the combination of SAR442720 and pembrolizumab. |
up to 2 years | |
Secondary | Time to Response (TTR) | Part 2 and 3B:
Time to response (TTR) defined as the time from the first administration of investigational medicinal product (IMP) to the first documented evidence of PR or CR determined by the Investigator per RECIST v1.1 (for NSCLC). |
up to 2 years | |
Secondary | Clinical Benefit Rate (CBR) | Part 2 and 3B:
Clinical benefit rate (CBR) including confirmed CR or PR at any time or stable disease (SD) of at least 6 months (determined by the Investigator per RECIST v1.1. |
up to 2 years | |
Secondary | Disease Control Rate (DCR) | Part 2 and 3B:
Disease control rate (DCR) including confirmed CR or PR or stable disease (SD) as determined by the Investigator per RECIST v1.1. |
up to 2 years | |
Secondary | Progression free survival (PFS) | Part 2 and 3B:
Progression free survival (PFS), defined as the time from the date of first IMP administration to the date of the first documented disease progression determined by the Investigator as per RECIST v1.1 or death due to any cause, whichever occurs first. |
up to 2 years | |
Secondary | Part 3A: Plasma concentrations of SAR442720 | up to 2 years | ||
Secondary | Part 3A: Plasma concentrations of adagrasib | up to 2 years | ||
Secondary | Objective Response Rate (ORR) of SAR442720 and adagrasib | Part 3A:
ORR of SAR442720 and adagrasib in all participants. ORR of combination therapy with SAR442720 and adagrasib will be based on RECIST v1.1. |
up to 2 years | |
Secondary | Duration of Response (DOR) of SAR442720 and adagrasib | Part 3:
DOR of SAR442720 and adagrasib in all participants. ORR of combination therapy with SAR442720 and adagrasib will be based on RECIST v1.1. |
up to 2 years | |
Secondary | Part 3B: Plasma concentrations of SAR442720 and adagrasib | up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02226289 -
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
|
Phase 2 | |
Terminated |
NCT02566421 -
Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery
|
N/A | |
Completed |
NCT01606033 -
Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating
|
N/A | |
Completed |
NCT00525057 -
Dalteparin in Preventing DVT in Participants With Cancer
|
N/A | |
Terminated |
NCT03871348 -
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02775292 -
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
|
Phase 1 | |
Recruiting |
NCT05617716 -
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
|
Phase 2 | |
Active, not recruiting |
NCT05103358 -
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
|
Phase 2 | |
Recruiting |
NCT02560311 -
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
|
N/A | |
Completed |
NCT02492711 -
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
|
Phase 3 |